What are the potential benefits of PYY (Peptide YY)?

Appetite suppression via arcuate nucleus Y2 receptor activation. Ileal brake contribution: slowing of gastric emptying and GI transit. Calorie-proportional release provides physiological meal termination. Intranasal PYY: clinically meaningful weight loss in Phase II trials. Complementary to GLP-1 for combination appetite suppression approaches

What compounds work synergistically with PYY (Peptide YY)?

PYY (Peptide YY) has been studied alongside Semaglutide, GLP-1, Oxyntomodulin for potential synergistic effects.

PYY (Peptide YY) — Mechanism, Benefits, Research & Synergies

Overview

Peptide YY (PYY) is a 36-amino acid gut peptide released from L-cells of the distal intestine and colon in proportion to caloric intake. The truncated form PYY(3-36), generated by DPP-4 cleavage, is the predominantly circulating active form and acts via Y2 receptors in the hypothalamic arcuate nucleus to suppress appetite and reduce food intake. PYY is a major component of the physiological 'ileal brake' mechanism and is often combined with GLP-1 in emerging obesity therapeutics. Intranasal PYY administration has shown promising weight loss results in Phase II trials.

Mechanism of Action

PYY(3-36) preferentially binds Y2 receptors (NPY receptor family, Gi/o-coupled GPCR) in the arcuate nucleus of the hypothalamus, where it inhibits NPY/AgRP neurons (appetite-promoting) while indirectly promoting POMC/CART neuron activity (appetite-suppressing). This shifts the hypothalamic balance toward satiety. PYY also activates Y2 receptors in the vagal sensory ganglia and enteric nervous system, slowing GI transit and inhibiting pancreatic secretion. The combination of PYY with GLP-1 targets multiple complementary satiety pathways, explaining additive appetite suppression in combination therapies.

Potential Benefits

Appetite suppression via arcuate nucleus Y2 receptor activation
Ileal brake contribution: slowing of gastric emptying and GI transit
Calorie-proportional release provides physiological meal termination
Intranasal PYY: clinically meaningful weight loss in Phase II trials
Complementary to GLP-1 for combination appetite suppression approaches

Research Dosage Notes

The following reflects doses used in published research studies. This is not medical advice.

Intranasal research protocols: 200-400 mcg per nostril. Oral/injectable clinical trial dosing under investigation.

Amino Acid Sequence

Tyr-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2 (PYY full); PYY(3-36) from Pro3

Side Effects & Safety

Nausea (dose-dependent)
Reduced appetite (intended effect)
GI transit slowing (constipation at high doses)

Synergistic Compounds

The following compounds have been studied alongside PYY (Peptide YY) for potential complementary or synergistic effects:

SemaglutideGLP-1Oxyntomodulin

Learn More

Beginner's GuideNew to peptides? Start here Stacking GuideSynergistic combinations Administration RoutesSubQ, IM, oral, nasal & more Reconstitution CalculatorCalculate exact dosing Peptides vs SARMsFull comparison How Peptides Are MadeSPPS, purification & QC

References & Further Reading

[object Object]
[object Object]

Quick Facts

Molecular Weight	4310.0 g/mol (full PYY); 4056.7 g/mol (PYY 3-36)
Research Status	Endogenous peptide: extensively characterized. PYY(3-36) intranasal (NN9748): Phase II trials by Novo Nordisk showing 9–12% weight loss. Multiple combination approaches in development.

More Peptides in This Category

Tesamorelin AOD-9604 Fragment 176-191 Kisspeptin Follistatin-344 MOTS-c

PYY (Peptide YY)